Coventry, UK, 17th November 2017 / Sciad Newswire / Medherant is delighted to announce they have been awarded the ‘Excellence in Science & Technology Award’ at the Coventry Telegraph Business Awards last night. These Awards are a celebration of companies in Coventry and Warwickshire which have achieved success for themselves, their staff and their customers.
The award recognises Medherant’s rapid progress and innovation in the development of next-generation transdermal drug delivery patches. Medherant, founded by Professor David Haddleton and the University of Warwick in 2015, has created a drug delivery platform, TEPI Patch®, designed to address many of the disadvantages of previous transdermal drug delivery patches. It enables a wider range of drugs to be delivered through the skin, has increased drug loading capacity, and provides a better patient user experience than patches currently on the market.
Medherant has also developed a high-throughput system for assessing the rate of drug delivery from its patches, which enables the company to rapidly test a range of potential formulations for each drug and optimise the final product. The company is already working with pharmaceutical companies to test their drugs in its TEPI Patch® platform.
Nigel Davis, CEO Medherant, commented: ‘This award is validation of the potential of our TEPI Patch® technology to revolutionise the transdermal drug delivery sector. We have continued to grow an excellent team and to partner with top companies from around the world as we look forward to progressing our technology further.’
The Coventry Telegraph Business Awards aim to celebrate success, recognise achievement and highlight the innovative people and companies in Coventry and Warwickshire who are putting the region on the map by boosting the economy while making a positive contribution to the local community. The finalists were selected and judged on the quality of their products and services, their dedication to sales performance, their commitment to innovation and the sustainability of their business.
Medherant would like to thank Coventry Telegraph Business Awards for organising the event, and Liberty House Group for sponsoring this award.
For further information, contact:
Nigel Davis, CEO
T: +44 (0)24 7632 3060
Media Relations, Sciad Communications
Deborah Cockerill / Emma Pickup
T: +44 (0)20 7470 8801
Notes to Editors
Medherant Ltd is a leading developer of next-generation transdermal drug delivery patches. The Company was founded by Professor David Haddleton and the University of Warwick in 2015.
Medherant has built upon its founders’ world-leading expertise in bio-adhesives and polymer chemistry to create adhesive drug delivery patches that overcome many of the limitations of patches currently on the market:
- Its TEPI Patch® technology can be used with a wider range of drugs, including those that are not suitable for oral administration.
- The amount of drug that can be loaded into the patch is greater, enabling the development of more effective transdermal therapies.
- The TEPI Patch® contains a novel adhesive which will provide a better patient experience as the patch sticks to the skin for longer, is less painful to remove, and does not leave a mark on the skin.
Medherant is developing products containing proven drugs that it intends to license prior to commercialisation. The Company’s first product is an ibuprofen patch. Manufacture for clinical trials will take place at AdhexPharma in France in the second half of 2017.
Medherant also runs feasibility studies that give companies the opportunity to see the benefits of delivering their drugs with TEPI Patch® technology. Medherant seeks partnerships with companies wishing to extend the commercial life of their products or those that have drugs that cannot be delivered orally at sufficient dosage.
Medherant is backed by Mercia Technologies PLC, a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia has named Medherant as one of their Emerging Stars within its Life Sciences & Biosciences portfolio.
For more information, please see www.medherant.co.uk